The time we are spending on digital devices is on the rise, and it’s unlikely to slow down any time soon. With more and more apps, games, and social media options, we have all become more dependent on smartphones, tablets, and other electronic devices.
Over the past few years, various diagnostics have been introduced to help clinicians identify inflammatory conditions on the ocular surface more readily and, therefore, provide treatment to patients earlier in their disease states.
Approaching dry eye from a systemic standpoint can potentially benefit patients in the long term and improve the quality of care we provide. Here are a few key considerations that should be made when assessing dry eye as a potential systemic symptom.
Rapid Pathogen Screening Inc. (RPS) has received a Clinical Laboratory Improvement Amendments (CLIA) waiver from the FDA for its rapid, disposable, in-office test (InflammaDry) to aid in the diagnosis of dry eye disease.